Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates are more engaged with the scientific and research community in comparison to some other disease and patient focus groups. By collaborating with rare disease patients, their families and various stakeholders involved on the design, positioning and subsequent enrollment of clinical trials, studies can be completed faster and more efficiently. PRA Health Sciences' Scott Schliebner (Vice President, Rare Diseases, Scientific Affairs) and Altair da Silva (Senior Manager, Patient Access and Recruitment Services) are joined by Neil Weisman (Executive Vice President and General Manager at Blue Chip Marketing) to discuss the patient voice and the importance of patient and caregiver insight.
Clinical Data Manager
PRA Data Managers play an integral role in the successful delivery of data management deliverables to meet internal and external client needs. They…
Evidence-Based and Site Focused Strategies to Enhance Clinical Trial Enrollment
Evidence-Based and Site-Focused Strategies to Enhance Clinical Trial Enrollment
Strong Site Selection Leads To Success
A randomized, double-blind, placebo-controlled Phase III study of Study Drug versus placebo for patients with advanced gastrointestinal stromal…